From Wikipedia, the free encyclopedia
Jump to: navigation, search
Monoclonal antibody
Type Whole antibody
Source Human
Target IGF-1 receptor
Clinical data
Routes of
ATC code
  • none
CAS Number
  • none
Chemical and physical data
Formula C6500H10052N1724O2036S44
Molar mass 146.3 kg/mol
 NYesY (what is this?)  (verify)

Cixutumumab (IMC-A12) is a human monoclonal antibody for the treatment of solid tumors.[1][2]

This drug was developed by ImClone Systems, since acquired by Eli Lilly, using phage display technology from Dyax.

It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the ligand IGF-1 and subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.[3]


Phase II clinical trials have been completed in patients with non-small cell lung cancer,[4][5] [6] metastatic rhabdomyosarcoma,[7] metastatic prostate cancer,[8] metastatic pancreatic cancer,[9] metastatic esophageal cancer,[10] bone cancer,[11][12] sarcoma,[13] solid tumors,[14] ocular melanoma,[15] hepatocellular carcinoma,[16][17], breast cancer[18] and other forms of cancer. Despite these extensive trials, more than 45 phase I and II clinical trials in total, phase III trials have never been undertaken and Eli Lilly has removed cixutumumab from their development pipeline.[19]


  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Cixutumumab American Medical Association.
  2. ^ McKian, KP; Haluska, P (2009). "Cixutumumab". Expert Opinion on Investigational Drugs. 18 (7): 1025–33. PMC 2939377Freely accessible. PMID 19548856. doi:10.1517/13543780903055049. 
  3. ^ [1] National Cancer InstituteTemplate:Http://
  4. ^
  5. ^
  6. ^
  7. ^
  8. ^
  9. ^
  10. ^
  11. ^
  12. ^
  13. ^
  14. ^
  15. ^
  16. ^
  17. ^
  18. ^
  19. ^